#imids Suchergebnisse
#multidisciplinar23 El Dr. Menchén habla desde el punto de vista del digestólogo. ¿Qué determinantes genéticos influyen en las #IMIDs? ⏺️Sistema inmune innato ⏺️Autofagia ⏺️Activación, proliferación y supervivencia de linfocitos T ⏺️Barrera intestinal
Less than 2 weeks until Part 2 of our Interdisciplinary Webinar on the IMID Forum!!! 🥳 Remember, its free to sign up!!! So what are you waiting for? #Rheumatology #IMIDs ow.ly/cfH350XfsbY
Have you seen our webinar lineup? 🤩 Our interdisciplinary webinar will feature talks from Professors Iain McInnes and Melinda Gooderham and Dr Grace Wright, as they provide more insights into improving patient care with an interdisciplinary IMID approach. Register today to
Stuart Conway @conway_group about a bump-and-hole approach based on #IMiDs and IKZF1/3. Broad potential application space in chemical biology, target validation but also as switch for therapeutic biomacromolecules such as CAR-T cells. #EFMCISMC24 @EuroMedChem
#OctoberIssue | Targeting inflammatory mechanisms of cardiovascular pathology in rheumatic immune-mediated inflammatory diseases (#IMIDs) and considerations for the diagnosis and management of cardiovascular involvement across rheumatic #IMIDs. bit.ly/3XWK9q7
🚨 Faculty Reveal! 🚨 Dr. Grace Wright joins Chair Iain McInnes for Part 2 of our Interdisciplinary webinar! 🧠💡 📅 10 Nov | ⏰ 16:00 GMT Another speaker reveal coming soon… stay tuned! 👀 🔗 #IMIDs #Webinar #GraceWright #PatientCare #MedicalEducation 🔗 Registration is
Chai et al. observed that #UPA is effective in treating #IMIDs like RA, axSpA, PsA, CD, and UC. Read the summary here:🔗ow.ly/IWPW50WNtre
The evidence you're mentioning highlights the complexity of treating immune-mediated inflammatory diseases (#IMIDs). It's intriguing to see that Advanced Combination Treatment (ACT) may not benefit rheumatological conditions but shows promise in helping those with Inflammatory
#multidisciplinar23 Dr. Queiro: Las enfermedades inflamatorias inmunomediadas #IMIDs no son raras, con una prevalencia del 6% en el mundo occidental ✔️Enfermedades con alto poder discapacitante ✔️Potencial de daño estructural y daño orgánico ✔️Es común la concurrencia de 2 o más
Hence we do need ‘Partnership in Prevention ‘ Why this approach ✅ Shared risk factors for #IMIDs including #IBD and non communicable diseases ✅ Use existing frameworks in prevention 📌 Infrastructure 📌 Regulations
Dejemos de mirar hacia otro lado: MÁS del 10% de pacientes con enfermedades inmunomediadas, #IMIDs, cumplen criterios de #Fibromialgia ¿La tratamos adecuadamente?
Cross-sectional study of 50 SLE patients, 24% had fibromyalgianess, and 18% experienced widespread pain. Fibromyalgianess in SLE patients primarily reflects heightened pain sensitivity and symptom severity rather than SLE disease activity. buff.ly/4jzNxQG
#JAKi use in #IMIDs just got a major update-expanded indications, tighter safety guidance, & new monitoring recommendations. “In our view, the update is more specific with what we know today,” said Josef Smolen, MD. bit.ly/42imUI6 @MedUni_Wien @eular_ARD
The way our immune cells age differs substantially by sex, from single-cell analysis of ~1,000 people. Implications for propensity for autoimmune diseases (women), vulnerability to cancer (men), immunosenescence and inflammaging @NatureAging nature.com/articles/s4358…
Hoy el #equipoGTEII en #aCadeMiO @sefh_ con @elelobmat hablando del proyecto CMO en #IMIDs @mapex_sefh
In the 8 years since the discovery that Celgene’s #IMiDs degrade oncogenic transcription factors by “gluing” them to E3 ubiquitin #ligases, over a dozen #biotechs have developed molecular glue degraders. See where this field is headed > (FREE with reg) ow.ly/X4l250Mkkoy
Join us on June 08, 2024 for Multidisciplinary Care in IBD @MCIBD_Can for an interactive day on the #multidisciplinary approach to managing IBD and #IMIDs in #preconception and #pregnancy, and bringing together practitioners from diverse specialties including gastroenterology,
📢Today is #WorldPsoriasisDay! 🌍At CNAG, we support their research through the European project DocTIS 🎯Our objetive: to improve treatment efficacy by identifying new combinations of existing drugs that enhance each other’s effects #InflammatoryDiseases #IMIDs #Horizon2020
💥 Tomorrow is #WorldPsoriasisDay! 👀 Created by @psoriasisifpa to raise awareness of #PsoriaticDisease, including psoriasis & psoriatic arthritis. 👨👩👧👦 2024's focus: family support. 👉 Learn more: doctis.eu/world-psoriasi… 📓 Check your country's agenda! #PsoriaticDiseaseAndFamily
Ready for presenting our poster "LABOUR PRODUCTIVITY GROWTH IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES UNDERGOING BIOLOGICAL OR JANUS KINASE INHIBITORS TREATMENT" @farupeib @ibsalut @asmen_ibsalut @navetahealth #eahp2024 #Workdisability #IMIDs #biologictherapies
👇 The full impact ( bidirectional - ‘positive or negative’) may not be known for few more years or another generation 🤔 The impact on #IMIDs ..
SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade nature.com/articles/s4158…
nature.com
SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade
Nature - mRNA vaccines targeting SARS-CoV-2 also sensitize tumours to immune checkpoint inhibitors.
🆕steps in the field of Immune-Mediated Inflammatory Diseases (#IMIDs) #research 💉As part of @DoctisEU, the EU-funded initiative to improve lives of IMIDs patients, #CNAG has participated in the last assemblies 🎯Challenges: data security, standardization & resource allocation
Por estos motivos, hemos propuesto que las #IMIDs sean incluidas entre los grupos de cribado universal de esteatosis hepática metabólica, con el objetivo de descartar de forma sistemática una #EHmet, especialmente con fibrosis significativa o avanzada. journals.lww.com/hep/fulltext/2…
The way our immune cells age differs substantially by sex, from single-cell analysis of ~1,000 people. Implications for propensity for autoimmune diseases (women), vulnerability to cancer (men), immunosenescence and inflammaging @NatureAging nature.com/articles/s4358…
📊 Turning data into better treatment decisions 🔬 Sergio Martínez (@IMIDomics) shares how data analysis helps understand patient responses and identify effective drug combinations in #IMIDs. 🔎 doctis.eu/sergio-martine… #DataScience #DocTISProject #IMIDResearch #EUResearch
Perhaps we need prevention and earlier treatments. Specially in #IMIDS screening for MASLD should become routine in first diagnosis. #IBD #Crohn #UC #ECCO @geteccu @aegastro @Bealoquebea @_Sandragm @MAriasLoste @DrJavierCrespo
#LiverTwitter Just published our MASH analysis and the uncomfortable takeaway is even the best therapies still leave 35 to 70 percent of patients without meaningful response which says more about the complexity of the biology than the drugs themselves sciencedirect.com/science/authSh…
🩺 On #WorldHealthDay 2026, @WHO highlights how science drives global health 🔬 Progress depends on cooperation across researchers, clinicians & institutions. #DocTISProject applies this approach to advance treatments for #IMIDs 👉 doctis.eu #TogetherForScience
👩🔬 Meet the people behind #DocTISProject! 🔬 In our first young researchers interview, Yolanda Guillén (@IMIDomics) shares how advanced molecular and computational technologies help better understand patient responses. 🔎 doctis.eu/yolanda-guille… #IMID #IMIDs #EUResearch
🧬 The #DocTISProject held its final Scientific Advisory Board meeting as we move towards completion in June 2026. 🙏 We thank the Board for their continuous guidance and support, helping advance progress in #IMIDs and #AutoimmuneTherapies. 🌐 doctis.eu #IMID
🧬 What is #DocTISProject? 🩺 #IMIDs affect millions worldwide, but not all patients respond in the same way. 🔬 DocTIS combines clinical and molecular data with systems biology to advance more personalised treatments. 🔎 Learn more: doctis.eu #IMIDResearch
Fantástica colaboración @SEReumatologia @geteccu !! 👏🏻👏🏻@jesussanzsanz44 #multidisciplinaridad #IMIDs
En esta serie exclusiva de dos videos exploramos cómo herramientas como #ChatGPT están impactando la investigación, el diagnóstico y el abordaje de las #IMIDs, y analizamos las tecnologías emergentes que están redefiniendo el cuidado de la salud. #IAenSalud #InnovaciónMédica
💊 Advancing combination therapies for #IMIDs requires robust molecular data and strong clinical–research integration. 📢 Dr @hoheyn (@cnag_eu) presented Work Package 4 at the #DocTISProject webinar, focusing on molecular data generation from IMID Biobank patients. #IMID
The study led by @cnag_eu and published in @NatureMedicine, which uses data from the #DocTISProject and maps cellular inflammation at an unprecedented scale, has been featured on one of Spain’s main national TV channels. More info:👉 doctis.eu/cellular-infla… #SingleCell #IMIDs
doctis.eu
DocTIS study on cellular inflammation in Nature Medicine
Is publication in Nature Medicine reflects the scientific relevance of DocTIS data and its contribution to high-impact international research.
🙌¡Nuestro atlas de la inflamación, de nuevo en TV! Un grupo de investigadores de CNAG publican el 1º atlas celular de la inflamación, que ha servido para desarrollar una herramienta IA para mejorar el diagnóstico de pacientes 📺Fuente: @A3Noticias 🔗cnag.eu/news/first-cel…
🧑⚕️#Debate recommends cross-speciality collaborative care in complex immune-mediated inflammatory diseases - treating the person living with the condition #IMIDs #rheumat #gastro #ophthalm #derm link.springer.com/article/10.118…
💊 Patient selection and characterisation are key to research on combination therapies for #IMIDs. 📢 During a #DocTISProject webinar, Dr Maria López Lasanta from H@vallhebron hospital presented the clinical features of #IMID-Biobank patients within WP3 (Patient Selection).
Hence we do need ‘Partnership in Prevention ‘ Why this approach ✅ Shared risk factors for #IMIDs including #IBD and non communicable diseases ✅ Use existing frameworks in prevention 📌 Infrastructure 📌 Regulations
🔬 #DocTISProject has been granted a six-month extension by @EU_Commission to complete its clinical trial in #IMIDs, ensuring robust patient follow-up and high-quality final results. 🔗 doctis.eu/doctis-six-mon… #immunemediated #IMID #AutoimmuneTherapies #IMIDResearch
¿Todavías no nos sigues? Entra en Youtube, suscríbete y repasa los updates en formato webinar: Últimas 5 sesiones ▶️ #Neurología ▶️ #IMIDs ▶️ #Angioedema hereditario ▶️ Enfermedades #Infecciosas ▶️ #Oftalmología 📽️ Canal Youtube #FARUPEIB👇 youtube.com/@FARUPEIB
💊 The #DocTISProject hosted a webinar earlier this year on discovering combination therapies for Immune-Mediated Inflammatory Diseases #IMIDs. 📢 Dr. Sara Marsal from @vallhebron & @VHIR_ introduced the project, outlining its scope and objectives. #IMID
Less than 2 weeks until Part 2 of our Interdisciplinary Webinar on the IMID Forum!!! 🥳 Remember, its free to sign up!!! So what are you waiting for? #Rheumatology #IMIDs ow.ly/cfH350XfsbY
Have you seen our webinar lineup? 🤩 Our interdisciplinary webinar will feature talks from Professors Iain McInnes and Melinda Gooderham and Dr Grace Wright, as they provide more insights into improving patient care with an interdisciplinary IMID approach. Register today to
🚨 Faculty Reveal! 🚨 Dr. Grace Wright joins Chair Iain McInnes for Part 2 of our Interdisciplinary webinar! 🧠💡 📅 10 Nov | ⏰ 16:00 GMT Another speaker reveal coming soon… stay tuned! 👀 🔗 #IMIDs #Webinar #GraceWright #PatientCare #MedicalEducation 🔗 Registration is
¿Todavías no nos sigues? Entra en Youtube, suscríbete y repasa los updates en formato webinar: Últimas 5 sesiones ▶️ #IMIDs ▶️ #Angioedema hereditario ▶️ Enfermedades #Infecciosas ▶️ #Oftalmología ▶️ #Vitíligo 📽️ Canal Youtube #FARUPEIB👇 youtube.com/@FARUPEIB
#OctoberIssue | Targeting inflammatory mechanisms of cardiovascular pathology in rheumatic immune-mediated inflammatory diseases (#IMIDs) and considerations for the diagnosis and management of cardiovascular involvement across rheumatic #IMIDs. bit.ly/3XWK9q7
Stuart Conway @conway_group about a bump-and-hole approach based on #IMiDs and IKZF1/3. Broad potential application space in chemical biology, target validation but also as switch for therapeutic biomacromolecules such as CAR-T cells. #EFMCISMC24 @EuroMedChem
🆕steps in the field of Immune-Mediated Inflammatory Diseases (#IMIDs) #research 💉As part of @DoctisEU, the EU-funded initiative to improve lives of IMIDs patients, #CNAG has participated in the last assemblies 🎯Challenges: data security, standardization & resource allocation
🔬 #DocTISProject has been granted a six-month extension by @EU_Commission to complete its clinical trial in #IMIDs, ensuring robust patient follow-up and high-quality final results. 🔗 doctis.eu/doctis-six-mon… #immunemediated #IMID #AutoimmuneTherapies #IMIDResearch
Qué buena tarde en #farmaimpulso @JanssenESP Inteligencia artificial, revisión de seguridad con @rocioasensi de fármacos biológicos, iJaks y otros, infecciones en pacientes con #imids y humanización con @ana_alvarezd Congrats a todxs!!
Hoy el #equipoGTEII en #aCadeMiO @sefh_ con @elelobmat hablando del proyecto CMO en #IMIDs @mapex_sefh
#JAKi use in #IMIDs just got a major update-expanded indications, tighter safety guidance, & new monitoring recommendations. “In our view, the update is more specific with what we know today,” said Josef Smolen, MD. bit.ly/42imUI6 @MedUni_Wien @eular_ARD
#multidisciplinar23 El Dr. Menchén habla desde el punto de vista del digestólogo. ¿Qué determinantes genéticos influyen en las #IMIDs? ⏺️Sistema inmune innato ⏺️Autofagia ⏺️Activación, proliferación y supervivencia de linfocitos T ⏺️Barrera intestinal
#multidisciplinar23 Dr. Queiro: Las enfermedades inflamatorias inmunomediadas #IMIDs no son raras, con una prevalencia del 6% en el mundo occidental ✔️Enfermedades con alto poder discapacitante ✔️Potencial de daño estructural y daño orgánico ✔️Es común la concurrencia de 2 o más
In the 8 years since the discovery that Celgene’s #IMiDs degrade oncogenic transcription factors by “gluing” them to E3 ubiquitin #ligases, over a dozen #biotechs have developed molecular glue degraders. See where this field is headed > (FREE with reg) ow.ly/X4l250Mkkoy
Chai et al. observed that #UPA is effective in treating #IMIDs like RA, axSpA, PsA, CD, and UC. Read the summary here:🔗ow.ly/IWPW50WNtre
Big news for #JAKinhibitors in #IMIDs: Expanded indications, refined safety guidance, & updated monitoring recs. “The update is more specific with what we know today,” said Josef Smolen, MD. bit.ly/42imUI6 #Rheumatology #AutoimmuneCare #JAKiUpdate @MedUni_Wien @eular_ARD
🐦 📢 El próximo 10 de octubre participaré en la reunión “Nuevos Horizontes en IMIDs: Enfoque 360º” en Barcelona. Presentaré la ponencia “Mejorando el seguimiento del paciente”, dentro de la visión del farmacéutico. #IMIDs #FarmaciaHospitalaria #AtenciónFarmacéutica #Salud
Ready for presenting our poster "LABOUR PRODUCTIVITY GROWTH IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES UNDERGOING BIOLOGICAL OR JANUS KINASE INHIBITORS TREATMENT" @farupeib @ibsalut @asmen_ibsalut @navetahealth #eahp2024 #Workdisability #IMIDs #biologictherapies
Os esperamos en una hora 🚀 📆 Update #IMIDs 16.30h ✏️ Incripciones f.mtr.cool/ldsjrphotq 🎙️Ponentes @frmoranta de @IBDBellvitge / @hbellvitge Joan Garcias Ladaria de #Dermatología / @SonEspases Juan Carlos Quevedo. #Reumatología / H.U. de Gran Canaria Dr. Negrín
Something went wrong.
Something went wrong.
United States Trends
- 1. #COYS N/A
- 2. Villa N/A
- 3. Mo Wagner N/A
- 4. #MiamiGP N/A
- 5. Ryan Walker N/A
- 6. Ben Rice N/A
- 7. Chase Burns N/A
- 8. Lauren Betts N/A
- 9. Duncan Robinson N/A
- 10. Tottenham N/A
- 11. Rolling Stone N/A
- 12. Kimi Antonelli N/A
- 13. Leclerc N/A
- 14. De Zerbi N/A
- 15. Braxton Ashcraft N/A
- 16. Liverpool N/A
- 17. #RaiseIt N/A
- 18. #Wurth400 N/A
- 19. Carrick N/A
- 20. ALL RISE N/A